What is Cellectis?
Founded in 1999 and headquartered in Paris, Cellectis operates at the intersection of biotechnology and pharmaceutical manufacturing. The company is recognized for its pioneering work in developing innovative pharmaceutical products, leveraging advanced technology infrastructure to address unmet medical needs. Since its public listing in 2019, Cellectis has transitioned into a mature enterprise, balancing its B2B and B2C market presence with a sophisticated approach to clinical development. By integrating mobile applications and digital health tools into its operational framework, the company continues to refine its delivery of complex therapeutic solutions, positioning itself as a key innovator in the global life sciences landscape.
How much funding has Cellectis raised?
Cellectis has raised a total of $521.5M across 5 funding rounds:
Corporate Investment
$22.2M
Stock Offering
$129M
Stock Offering
$163.7M
Other Financing Round
$164M
Debt
$42.6M
Corporate Investment (2014): $22.2M with participation from Merlin Nexus, Ridgeback Capital, venBio, OrbiMed, and Aquilo Capital Management
Stock Issuance/Offering (2015): $129M led by Undisclosed
Stock Issuance/Offering (2018): $163.7M supported by Citigroup, Goldman Sachs & Co, and Barclays
Other Financing Round (2018): $164M featuring Undisclosed
Debt (2022): $42.6M backed by European Investment Bank
Key Investors in Cellectis
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Barclays
Barclays PLC is a British multinational universal bank providing a wide range of financial services, including corporate and investment banking, to global institutions.
What's next for Cellectis?
Looking ahead, the strategic deployment of the $42.6M investment is expected to focus on scaling manufacturing capabilities and advancing late-stage clinical trials. As the company continues to mature, the emphasis will likely shift toward commercialization strategies and the optimization of its therapeutic portfolio. By leveraging its established relationships with global financial institutions and specialized life sciences investors, Cellectis is well-positioned to navigate the complexities of the international healthcare market. The firm's ability to secure diverse forms of financing, ranging from equity offerings to debt instruments, provides the necessary liquidity to sustain long-term growth and drive shareholder value in an increasingly competitive biopharmaceutical environment.
See full Cellectis company page
